Short Interest in Progyny, Inc. (NASDAQ:PGNY) Increases By 41.0%

Progyny, Inc. (NASDAQ:PGNY) was the recipient of a significant growth in short interest in February. As of February 13th, there was short interest totaling 4,015,675 shares, a growth of 41.0% from the January 29th total of 2,847,787 shares. Based on an average daily trading volume, of 1,363,392 shares, the short-interest ratio is presently 2.9 days. Currently, 5.1% of the company’s stock are sold short. Currently, 5.1% of the company’s stock are sold short. Based on an average daily trading volume, of 1,363,392 shares, the short-interest ratio is presently 2.9 days.

Key Headlines Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue (EPS $0.48 vs. $0.38 est.; revenue $318.4M vs. ~$314M est.), showing year-over-year revenue growth. Read More.
• Positive Sentiment: Strong cash generation and shareholder returns: Progyny reported record $210.2M operating cash flow for the year and has repurchased ~6.5M shares under its authorization to date. Read More.
• Positive Sentiment: FY 2026 EPS guidance was raised above consensus (1.83–1.95 vs. ~1.55Street est.), indicating management expects better full‑year profitability despite near‑term revenue headwinds. Read More.
• Neutral Sentiment: Transcripts and slide deck from the earnings call are available for investors who want management detail on drivers (retention, pricing, membership growth) and cadence of benefits. Read More.
• Negative Sentiment: Near‑term revenue guidance disappointed: Q1 2026 revenue guidance ($319M–$332M) is below consensus (~$345M), which likely explains the sell‑off despite the EPS beat and stronger FY EPS outlook. Read More.
• Negative Sentiment: Short interest has risen materially (reported ~41% increase in shares sold short in February to ~4.0M shares, ~5.1% of float), increasing downside pressure and volatility. Read More.

Institutional Trading of Progyny

Institutional investors and hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Progyny by 57.1% in the 3rd quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock worth $15,156,000 after acquiring an additional 256,078 shares during the last quarter. Cresset Asset Management LLC boosted its position in shares of Progyny by 715.3% during the 2nd quarter. Cresset Asset Management LLC now owns 85,053 shares of the company’s stock valued at $1,871,000 after acquiring an additional 74,621 shares during the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Progyny by 88.0% during the second quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock worth $1,236,000 after purchasing an additional 26,310 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Progyny in the second quarter worth approximately $327,000. Finally, Fort Washington Investment Advisors Inc. OH increased its position in shares of Progyny by 33.1% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after purchasing an additional 412,395 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Stock Down 20.5%

Shares of NASDAQ:PGNY opened at $17.69 on Monday. The firm has a market capitalization of $1.53 billion, a PE ratio of 27.22, a P/E/G ratio of 1.12 and a beta of 1.01. The company has a 50-day moving average price of $23.90 and a two-hundred day moving average price of $23.11. Progyny has a twelve month low of $16.75 and a twelve month high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The company had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Canaccord Genuity Group raised their price objective on Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research note on Monday, November 17th. KeyCorp upped their target price on shares of Progyny from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 target price for the company in a report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a report on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.80.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.